• Oxytocin Signaling and Innate Defense After ELA

  2026-10-14

  Tan et al. report that a later developmental period of social deprivation in mice impaired adult looming-evoked defensive behavior and was associated with reduced oxytocin-receptor expression in the intermediate and deep superior colliculus. Circuit perturbation and partial rescue findings support an oxytocin-linked mechanism, while leaving important questions about visual processing, receptor function, developmental specificity, and translation unresolved.

• IEM 1460 and the Limits of Soman Evidence

  2026-10-14

  The supplied evidence supports a cautious distinction: APExBIO describes IEM 1460 as a selective AMPA receptor blocker, whereas the cited rat study evaluated the different compound IEM-1925. The study offers preclinical evidence for dual glutamate-receptor blockade in soman-related seizures, not evidence that IEM 1460 has the same effects.

• ECL Western Blotting Substrate: Evidence Scope

  2026-10-13

  ECL Western Blotting Substrate (SKU K2187) is described by APExBIO as a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent immunoblot signal capture. No matched research paper was identified, so performance claims and applicability beyond the supplier’s stated scope remain unverified.

• β-Galactosidase Staining and HNSCC Senescence

  2026-10-13

  Lysosomal β-galactosidase staining can provide a visible readout of enzyme activity relevant to senescence research, but it is not sufficient on its own to establish cellular senescence or explain cisplatin resistance. An article-in-press study links SLC25A1 to senescence-associated cisplatin resistance in HNSCC, while the supplied product description defines a narrower lysosomal enzyme target and does not document use of this particular kit.

• Procainamide Hydrochloride in Cisplatin Pregnancy Study

  2026-10-12

  A 2006 mouse study examined whether Procainamide Hydrochloride could accompany cisplatin during pregnancy without worsening developmental toxicity. The findings suggested no increase in cisplatin-associated embryotoxicity and modest improvement in several fetal endpoints, but the evidence remains limited to a preclinical model and does not establish safety or benefit in human pregnancy.

• MPP7, Polarity and Ovarian Cancer Progression

  2026-10-12

  A source-grounded overview of a 2024 study linking MPP7 expression with epithelial ovarian cancer prognosis, cell polarity, EMT-related signaling and malignant cell behaviors, while distinguishing reported findings from mechanistic interpretation and noting important limits on clinical applicability.

• Lactate, MRE11 and TNBC Radioresistance

  2026-10-11

  A source-grounded overview of Li et al. (2025), which links lactate-associated MRE11 Lys673 lactylation to DNA repair and radioresistance in triple-negative breast cancer, and interprets Saikosaponin D as a preclinical modulator of the HIF1α–HDAC5 pathway. The evidence supports a mechanistic hypothesis, not a clinical treatment claim or validation of a commercial Sodium Oxamate product.

• Lapatinib: From Kinase Potency to Evidence

  2026-10-09

  Lapatinib, also known as GW572016, is more than a potent EGFR and HER2 inhibitor. This evidence-focused analysis explains how to connect biochemical activity, receptor context, cellular phenotypes, and the 2026 dual-targeting study without overstating mechanism or translational relevance.

• AICAR and the Next Wave of Metabolic Translation

  2026-10-09

  AICAR provides a useful pharmacological lens for studying AMPK-linked energy metabolism, mitochondrial quality control, and inflammatory signaling. Grounded in a 2025 study of Lycium barbarum polysaccharide and sarcopenic obesity, this thought-leadership perspective distinguishes pathway engagement from therapeutic proof and outlines a translational framework for evaluating metabolic disease research programs.

• Optimizing Functional Platelets from hiPSCs

  2026-10-08

  A 2026 study presents an optimized differentiation scheme for producing functional platelets from human induced pluripotent stem cells. By integrating embryoid-body input refinement, human platelet lysate, and small-molecule modulation, the researchers report a 19-day process, higher platelet output, measurable clot activity, and lower estimated production costs, while leaving important questions about scalability and clinical translation unresolved.

• Ionizing Radiation and Altered Neural Differentiation

  2026-10-08

  Eom et al. showed that ionizing radiation can promote an altered neuronal differentiation program in C17.2 mouse neural stem-like cells, rather than producing only stem-cell loss. Their evidence connects neurite outgrowth and neuronal marker changes with PI3K-dependent p53 and STAT3–mGluR1 signaling, while also identifying a potentially abnormal glutamate-receptor profile.

• Pitavastatin (NK-104) Product Overview

  2026-10-07

  Pitavastatin, also known as NK-104, is product B1124 from APExBIO and is described as an HMG-CoA reductase inhibitor for conceptual cholesterol-biosynthesis, cardiovascular disease model, and atherosclerosis research. No directly matched paper evidence was provided.

• L-Ornithine: Urea Cycle Evidence & Research Limits

  2026-10-07

  L-Ornithine, also known as (S)-2,5-diaminopentanoic acid, is a non-proteinogenic urea cycle intermediate used to study nitrogen disposal and amino acid metabolism. A 2025 realgar-toxicity study linked hepatic OTC disruption with ornithine accumulation and astrocyte metabolic changes, but the findings remain model-specific rather than evidence of a human treatment effect.

• BglII Restriction Endonuclease Overview

  2026-10-06

  BglII is an APExBIO-supplied restriction endonuclease described for sequence-specific DNA cleavage. Available evidence is limited to product documentation; no matched peer-reviewed paper evidence was provided.

• 4-Phenylbutyric Acid in ER Stress Research

  2026-10-06

  A source-grounded overview of 4-Phenylbutyric acid and 4-PBA as research tools for studying endoplasmic reticulum stress, with emphasis on PFOS-related kidney-cell injury, evidence strength, conceptual applications, and limitations.

8621 records 1/575 page Next 12345 下5页 Last page